A telephone-based weight-loss intervention helped women with breast cancer and obesity lose almost 5% of their baseline body ...

The Metastatic Non-Small Cell Lung Cancer market size was valued ~21 billion in 2023 and is anticipated to grow with a ...

EMA validates Daiichi Sankyo & AstraZeneca’s type II variation MAA for Enhertu for previously treated patients with HER2 positive metastatic solid tumours: Tokyo Friday, Septemb ...

DESTINY-PanTumor02 is a global, multicenter, multi-cohort, open-label phase 2 trial evaluating the efficacy and safety of ENHERTU (5.4 mg/kg) for the treatment of previously treated HER2 expressing ...